Boston Financial Mangement buys $53,823,901 stake in Pfizer (PFE)

Pfizer (PFE) : Boston Financial Mangement scooped up 7,180 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 1,538,705 shares of Pfizer which is valued at $53,823,901.Pfizer makes up approximately 4.25% of Boston Financial Mangement’s portfolio.

Other Hedge Funds, Including , Lakeview Capital Partners boosted its stake in PFE in the latest quarter, The investment management firm added 2,077 additional shares and now holds a total of 83,393 shares of Pfizer which is valued at $2,917,087. Pfizer makes up approx 1.71% of Lakeview Capital Partners’s portfolio.Sandy Spring Bank reduced its stake in PFE by selling 22,639 shares or 16.58% in the most recent quarter. The Hedge Fund company now holds 113,892 shares of PFE which is valued at $3,978,248. Pfizer makes up approx 0.44% of Sandy Spring Bank’s portfolio.Benchmark Capital Advisors boosted its stake in PFE in the latest quarter, The investment management firm added 6,300 additional shares and now holds a total of 120,649 shares of Pfizer which is valued at $4,214,270. Pfizer makes up approx 3.32% of Benchmark Capital Advisors’s portfolio.Heritage Investors Management Corp reduced its stake in PFE by selling 4,131 shares or 0.96% in the most recent quarter. The Hedge Fund company now holds 426,794 shares of PFE which is valued at $15,637,732. Pfizer makes up approx 1.14% of Heritage Investors Management Corp’s portfolio.Cutler Group Lp reduced its stake in PFE by selling 30,985 shares or 44.66% in the most recent quarter. The Hedge Fund company now holds 38,394 shares of PFE which is valued at $1,394,086. Pfizer makes up approx 0.09% of Cutler Group Lp’s portfolio.

Pfizer opened for trading at $35 and hit $35.27 on the upside on Tuesday, eventually ending the session at $35.09, with a gain of 0.72% or 0.25 points. The heightened volatility saw the trading volume jump to 1,69,57,889 shares. Company has a market cap of $212,844 M.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.